DLL3 Targeted Therapy Market Size DLL3 Drugs Clinical Trials DLL3 Cancer Therapy Market Drugs Approval Insight [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Delhi, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Global DLL3 Targeted Therapies Market, Approved Drugs Dosage, Pricing & Clinical Trials Insight 2025 Report Finding and Highlights: Global & Regional Market Overview DLL3 Targeted Drugs Available In Market:1 Drug, Imdelltra (Tarlatamab) Approved Drug Dosage, Sales & Pricing Insight DLL3 Targeted Therapies Proprietary Platforms: 10 Platform Role of DLL3 As Diagnostic & Prognostic Markers DLL3 Targeted Drugs Clinical Trials Insight By Company, Indication and Phase: 10 Drugs Global DLL3 Targeted Therapies Clinical Development Trends By Indication Download Report: https://www.kuickresearch.com/report-dll3-fda-approved-dll3-targeted-therapies-dll3-companiesdll3-cancer-dll3-market-size-fore
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen Set to Report Q4 Earnings: Is a Beat in the Cards? [Yahoo! Finance]Yahoo! Finance
- EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASEPR Newswire
- Is Cutting DEI Deadly? FDA Stops Diversity Guidance In Clinical Trials [Forbes]Forbes
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Citigroup Inc. from $310.00 to $295.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $324.00 price target on the stock.MarketBeat
AMGN
Earnings
- 10/30/24 - Beat
AMGN
Sec Filings
- 12/6/24 - Form 4
- 12/3/24 - Form 4
- 11/6/24 - Form 4
- AMGN's page on the SEC website